News & Events

4 03, 2025

New RNA-Guided System Uncovered, Offering Promise for Precision Gene Editing Therapies

2025-03-04T16:43:54+00:00

TIGR (Tandem Interspaced Guide RNA) systems use RNA guides to target specific DNA sites, offering a compact and modular alternative to CRISPR. Scientists at MIT and the Broad Institute discovered over 20,000 TIGR-associated proteins, some capable of precise DNA cutting, potentially expanding genome...

New RNA-Guided System Uncovered, Offering Promise for Precision Gene Editing Therapies2025-03-04T16:43:54+00:00
26 02, 2025

Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities

2025-03-04T16:42:16+00:00

Avance Biosciences™ announces CLIA registration, expanding its high-complexity laboratory testing capabilities for clinical trials, regulatory submissions, and companion diagnostics. This milestone strengthens its commitment to high-quality, regulatory-compliant testing solutions that accelerate drug...

Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities2025-03-04T16:42:16+00:00
26 02, 2025

Gene Therapy Restores Vision in Children with AIPL1-Related Retinal Dystrophy

2025-02-26T17:15:05+00:00

A groundbreaking gene therapy using rAAV8.hRKp.AIPL1 has restored vision in 11 children with AIPL1-related retinal dystrophy (LCA4), who were blind at birth. Published in The Lancet, the study shows significant improvements in visual acuity and retinal preservation, supporting expedited approval...

Gene Therapy Restores Vision in Children with AIPL1-Related Retinal Dystrophy2025-02-26T17:15:05+00:00
7 11, 2024

Let’s find out if it’s TRICK or TREAT this Halloween!!!

2025-02-21T14:24:05+00:00

Well, well, well... it was a TREAT — and a big one for a lucky few! Avance fully embraced Halloween last Thursday with a costume contest, candy galore, and a pizza party. The costume contest was a great way to bring everyone together, with employees voting for winners in five fun categories [...]

Let’s find out if it’s TRICK or TREAT this Halloween!!!2025-02-21T14:24:05+00:00
6 11, 2024

Society for Immunotherapy of Cancer (SITC) – 2024

2025-03-14T18:56:09+00:00

Avance Biosciences is excited to announce its participation in the upcoming SITC Conference, taking place from November 6-10, 2024, in Houston TX. This premier event is focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. [...]

Society for Immunotherapy of Cancer (SITC) – 20242025-03-14T18:56:09+00:00
23 10, 2024

American Assoc. of Pharmaceutical Scientists (AAPS) PharmSci 360 Meeting – 2024

2025-03-14T18:53:33+00:00

Avance Biosciences™ offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise. [...]

American Assoc. of Pharmaceutical Scientists (AAPS) PharmSci 360 Meeting – 20242025-03-14T18:53:33+00:00
15 10, 2024

Immunogenicity & Bioassay Summit – 2024

2025-03-14T18:54:55+00:00

Avance Biosciences is excited to announce its participation in the upcoming Immunogenicity & Bioassay Summit, taking place from October 15-18, 2024, in Washington, DC. As the premier immunogenicity and bioassay event in the U.S., this summit provides an excellent platform for us to connect with industry [...]

Immunogenicity & Bioassay Summit – 20242025-03-14T18:54:55+00:00
17 09, 2024

CRISPR-Based Therapy Analytical Development Summit – 2024

2025-03-14T18:57:34+00:00

Avance Biosciences is excited to announce its participation in the upcoming 2nd CRISPR-Based Therapy Analytical Development Summit, taking place from September 17-19, 2024, in Boston, MA. This premier event is a key gathering for professionals and innovators in the gene editing and CRISPR fields.[...]

CRISPR-Based Therapy Analytical Development Summit – 20242025-03-14T18:57:34+00:00
20 08, 2024

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England

2024-08-20T13:52:29+00:00

Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel. Exa-cel is the world’s first CRISPR-based gene therapy and the first gene therapy available in Europe for treating severe beta-thalassaemia...

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England2024-08-20T13:52:29+00:00
6 08, 2024

FDA Approves First T Cell Receptor (TCR) Gene Therapy

2024-08-06T19:21:42+00:00

Tecelra is the first FDA-approved T cell receptor (TCR) gene therapy. The product is an autologous T cell immunotherapy composed of a patient’s own T cells. T cells in Tecelra are modified to express a TCR that targets MAGE-A4, an antigen expressed by cancer cells in synovial sarcoma...

FDA Approves First T Cell Receptor (TCR) Gene Therapy2024-08-06T19:21:42+00:00
Go to Top